In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis

Chen, Wenjie; Li, Hong; Yi, Jia; Lv, Meili; Li, Mingyuan; Feng, Ping; Hu, Huaizhong; Zhang, Lin

doi:10.1016/j.jaut.2006.11.001

Cited by 22 publications

(12 citation statements)

References 49 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One method that has been tried for depleting cells based on the expression of chemokine receptors, although not CCR6, is the fusion of chemokines and toxins. Fusions of diphtheria toxin and CXCL10 or CCL5 have been tested and shown to be effective in a mouse EAE model [140, 141]. Similarly, a fusion between the CCR4 ligand CCL17 and a truncated fragment of Pseudomonas exotoxin was able to eradicate an experimental CCR4-expressing cutaneous lymphoma [142].…”

Section: Expert Opinionmentioning

confidence: 99%

CCR6 as a possible therapeutic target in psoriasis

Hedrick

Lonsdorf

Hwang

et al. 2010

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

Importance of the field Psoriasis is a common, chronic autoimmune disease of the skin. Despite a number of effective treatments, new therapies are needed with enhanced efficacy, safety, and convenience. Chemokine receptors are G protein-coupled receptors that control leukocyte trafficking, and like other G protein-coupled receptors, are good potential drug targets. The chemokine receptor CCR6 is expressed on the Th17 subset of CD4+ T cells, which produces IL-17A/F, IL-22, TNF-α and other cytokines, and which has been implicated in the pathogenesis of psoriasis. CCR6 and its ligand, CCL20/MIP-3α, are highly expressed in psoriatic skin and CCR6 is necessary for the pathology induced in a mouse model of psoriasis-like inflammation. Areas covered in this review This review will summarize the evidence for the importance of the IL-23/Th17 axis, and in particular CCR6 and CCL20 in psoriasis, dating from 2000 to the present, and discuss the possibility of inhibiting CCR6 as treatment for the disease. What the reader will gain The review will inform the reader of the current thinking on the mechanisms of inflammation in psoriasis and the possible roles for CCR6 (and CCL20) in disease pathogenesis. Take home message We conclude that CCR6 should be investigated as a potential therapeutic target in psoriasis.

show abstract

Section: Expert Opinionmentioning

confidence: 99%

CCR6 as a possible therapeutic target in psoriasis

Hedrick

Lonsdorf

Hwang

et al. 2010

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

show abstract

“…Mice intramuscularly injected with the eukaryotik expression plasmid SRα coding for the CXCL10-specific immunotoxin DT390-IP-10 showed a delayed onset of EAE and milder symptoms. Immunohistochemical staining confirmed significantly reduced infil trat ing CXCR3 + cells in the inflammatory lesions of CNS from immunotoxin treated mice [36].…”

Section: Immunotoxinsmentioning

confidence: 76%

Gene therapy of multiple sclerosis

Furlan¹,

Maiorino²,

Gatta³

et al. 2010

Gene Therapy for Autoimmune and Inflammatory Diseases

View full text Add to dashboard Cite

Multiple sclerosis (MS) constitutes a difficult challenge for the design of innovative therapies: the aetiology is unknown, the pathogenesis only partially understood, and the whole process is multi-focal, chronic, and occurring beyond anatomical barriers, making the delivery of potentially therapeutic molecules difficult. Gene therapy, thus, constitutes a realistic alternative to ensure prolonged, and site-specific delivery of therapies. Recent advancements in the comprehension of the immunopathological processes leading to central nervous system inflammation, and the development of new gene therapy tools, such as RNA-interference, are rapidly leading to a large array of possibilities of intervention, documented in the present review in its animal model, experimental autoimmune encephalomyelitis (EAE). Since progressive forms of MS remain orphan of efficient therapies, the field is open for less conventional interventions such as gene therapy.

show abstract

“…CD64 or IgG receptors are overexpressed in the synovial macrophages in RA and hence anti-CD64-ricin IT showed effective clearance of activated synovial inflammatory macrophages in vitro [35]. The IT DT390-IP-10-Sra, containing interferon gamma-inducible protein 10 (IP-10) to target CXCR3 could effectively reduce the infiltrating CXCR3+ cells in experimental autoimmune encephalomyelitis (EAE) [36]. Another target moiety, the 'Regulated on Activation Normal T cells Expressed and Secreted' (RANTES) with DT390 has been used to target the chemokine receptor CCR5 [37].…”

Section: Immunotoxins In Autoimmune Disordersmentioning

confidence: 99%